匹多莫德联合阿莫西林-克拉维酸钾序贯疗法对急性扁桃体炎患儿症状改善及血清CD4^+/CD8^+水平的影响  

Effect of pidotimod combined with amoxicillin-clavulanate potassium sequential therapy on symptom improvement and serum CD4^+/CD8^+levels in children with acute tonsillitis

作　　者：刘海霞[1] Liu Haixia(Department of Otolaryngology,Children’s Hospital of Shanxi,Taiyuan 030013,China)

机构地区：[1]山西省儿童医院耳鼻咽喉科,太原030013

出　　处：《中国实用医刊》2019年第4期93-97,共5页Chinese Journal of Practical Medicine

摘　　要：目的探讨匹多莫德联合阿莫西林-克拉维酸钾序贯疗法对急性扁桃体炎患儿症状改善及血清CD4^+/CD8^+水平的影响。方法选取山西省儿童医院2017年4月至2018年4月收治的急性扁桃体炎患儿130例,根据随机数字表法分为研究组(n=65)和对照组(n=65)。对照组采用阿莫西林-克拉维酸钾序贯疗法治疗,研究组在对照组基础上加用匹多莫德治疗。比较两组治疗效果,临床症状改善(发热消退、扁桃体分泌物消退、咽痛消失、咽部充血消退)情况,不良反应发生率,治疗前后免疫功能指标[T淋巴细胞亚群(CD4^+/CD8^+、CD4^+/CD3^+、CD8^+/CD3^+)]及白细胞计数(WBC)、C-反应蛋白(CRP)及中性粒细胞百分比(NEUT%)变化情况。结果①治疗效果:研究组治疗总有效率[98.46%(64/65)]高于对照组[86.15%(56/65)],P<0.05;②临床症状改善情况:研究组发热消退、扁桃体分泌物消退、咽痛消失、咽部充血消退等时间短于对照组(P<0.05);③免疫功能:治疗后,研究组CD4^+/CD8^+、CD4^+/CD3^+水平高于对照组,CD8^+/CD3^+水平低于对照组(P<0.05);④实验室检测结果:治疗后,研究组WBC、CRP、NEUT%水平低于对照组(P<0.05);⑤不良反应:研究组[6.15%(4/65)]不良反应总发生率与对照组[3.08%(2/65)]比较差异未见统计学意义(P>0.05)。结论匹多莫德联合阿莫西林-克拉维酸钾序贯疗法治疗急性扁桃体炎患儿,能显著提高治疗效果,提高患儿免疫功能,减轻炎症反应,从而促进临床症状改善,安全可靠,具有较高应用价值。Objective To study the effects of pidotimod combined with amoxicillin-clavulanate potassium sequential therapy on the improvement in symptoms and serum CD4^+/CD8^+levels in children with acute tonsillitis.Methods A total of 130 children with acute tonsillitis admitted to Children's Hospital of Shanxi from April 2017 to April 2018 were enrolled in the study.And they were divided into study group(n=65)and control group(n=65)according to the random number table method.The control group was treated with amoxicillin-clavulanate potassium sequential therapy,and the study group was treated with pidotimod on the basis of treatment for the control group.The treatment effects,clinical symptoms improvement(fever regression,tonsil secretion regression,sore throat disappearance,pharyngeal congestion disappearance),the incidence of adverse reactions,immune function indicators before and after treatment(T lymphocyte subsets,including CD4^+/CD8^+,CD4^+/CD3^+,CD8^+/CD3^+)and changes in white blood cell count(WBC),C-reactive protein(CRP),and neutrophil percentage(NEUT%)were compared between the two groups.Results①The total effective rate of the study group was 98.46%(64/65),which was significantly higher than 86.15%(56/65)of the control group(P<0.05).②The fever disappearance time,the disappearance time of tonsil secretion,the disappearance time of sore throat,and the disappearance time of pharyngeal congestion of the study group were shorter than those in the control group(P<0.05).③After treatment,the levels of CD4^+/CD8^+and CD4^+/CD3^+in the study group were higher than those in the control group,and the level of CD8^+/CD3^+was lower than that in the control group(P<0.05).④After treatment,the WBC,CRP,NEUT%levels of the study group were lower than those of the control group(P<0.05).⑤The total incidence of adverse reactions in the study group was 6.15%(4/65),which was not significantly different from the 3.08%(2/65)in the control group(P>0.05).Conclusions Pidotimod combined with amoxicillin-clavulanate potassium sequenti

关 键 词：急性扁桃体炎 匹多莫德 阿莫西林-克拉维酸钾 免疫功能 

分 类 号：R766.18[医药卫生—耳鼻咽喉科]